HIV/AIDS

An HIV-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals

1. Nathaniel Erdmann
2. Wilton B. Williams
3. Stephen R. Walsh
4. Derek W. Cain
5. Matthew Clark
6. Ryan Tuck
7. Sommer Holmes
8. Benae Clardy
9. Andrew Foulger
10. Robert Parks
11. Margaret Barr
12. Amanda Eaton
13. Kevin O. Saunders
14. Nicole Grunenberg
15. Paul Edlefsen
16. Paul A. Goepfert
17. Kristen W. Cohen
18. Janine Maenza
19. Kenneth Mayer
20. Hong Van Tieu
21. Magdalena E. Sobieszczyk
22. Edith Swann
23. Huiyin Lu
24. Stephen C. De Rosa
25. Zachary K. Sagawa
26. Bob C. Lin
27. Robin E. Carrol
28. Krisha McKee
29. Nicole A. Doria-Rose
30. Mark K. Louder
31. M. Anthony Moody
32. Christopher B. Fox
33. Guido Ferrari
34. Robert J. Edwards
35. Priyamvada Acharya
36. S. Munir Alam
37. Georgia D. Tomaras
38. David C. Montefiori
39. Peter B. Gilbert
40. M. Juliana McElrath
41. Lawrence Corey
42. Barton F. Haynes
43. Lindsey R. Baden
44. the NIAID HVTN 133 Study Group

Reviewed by Rapid Reviews Infectious Diseases

Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study

1. Kwabena Asare
2. Yukteshwar Sookrajh
3. Johan van der Molen
4. Thokozani Khubone
5. Lara Lewis
6. Richard J Lessells
7. Kogieleum Naidoo
8. Phelelani Sosibo
9. Rosemary van Heerden
10. Nigel Garrett
11. Jienchi Dorward

Reviewed by Rapid Reviews Infectious Diseases

Do community-level factors play a role in HIV self-testing uptake, linkage to services and HIV-related outcomes? A mixed methods study of community-led HIV self-testing in rural Zimbabwe

1. Mary K. Tumushime
2. Nancy Ruhode
3. Melissa Neuman
4. Constancia Watadzaushe
5. Miriam Mutseta
6. Miriam Taegtmeyer
7. Cheryl C. Johnson
8. Karin Hatzold
9. Elizabeth L. Corbett
10. Frances M. Cowan
11. Euphemia L. Sibanda

Reviewed by Rapid Reviews Infectious Diseases

Gene dysregulation among virally suppressed people living with HIV links to non-AIDS defining cancer pathways

1. Bryan C. Quach
2. Eric Earley
3. Linran Zhou
4. Caryn Willis
5. Jesse A. Marks
6. Jeran K. Stratford
7. Fang Fang
8. Laura J. Bierut
9. M-J S. Milloy
10. Kanna Hayashi
11. Kora DeBeck
12. Dana B. Hancock
13. Ke Xu
14. Bradley E. Aouizerat
15. Eric O. Johnson

Reviewed by Rapid Reviews Infectious Diseases

Evaluation of Four Interventions Using Behavioral Economics Insights to Increase Demand for Voluntary Medical Male Circumcision in South Africa Through the MoyaApp: A Quasi-Experimental Study

1. Preethi Mistri
2. Silviu Tomescu
3. Simamkele Bokolo
4. Alexandra De Nooy
5. Pedro T. Pisa
6. Skye Grove
7. Laura Schmucker
8. Candice Chetty-Makkan
9. Lawrence Long
10. Alison Buttenheim
11. Brendan Maughan-Brown

Reviewed by Rapid Reviews Infectious Diseases

Population dynamics of HIV drug resistance during treatment scale-up in Uganda: a population-based longitudinal study

1. Michael A. Martin
2. Steven James Reynolds
3. Brian T. Foley
4. Fred Nalugoda
5. Thomas C. Quinn
6. Steven A. Kemp
7. Margaret Nakalanzi
8. Edward Nelson Kankaka
9. Godfrey Kigozi
10. Robert Ssekubugu
11. Ravindra K. Gupta
12. Lucie Abeler-Dörner
13. Joseph Kagaayi
14. Oliver Ratmann
15. Christophe Fraser
16. Ronald Moses Galiwango
17. David Bonsall
18. M. Kate Grabowski
19. the Rakai Health Sciences Program

Reviewed by Rapid Reviews Infectious Diseases

Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection

1. Kavidha Reddy
2. Guinevere Q Lee
3. Nicole Reddy
4. Tatenda JB Chikowore
5. Kathy Baisley
6. Krista L Dong
7. Bruce D Walker
8. Xu G Yu
9. Mathias Lichterfeld
10. Thumbi Ndung'u

• Curated by eLife

  eLife Assessment

  This fundamental, clearly written, and timely manuscript links the timing of ART with the kinetics of total and intact proviral HIV DNA. The conclusions are interesting and novel, and the importance of the work is high because the focus is on African women and clade C virus, both of which are understudied in the HIV reservoir field. The strength of the evidence is compelling. Overall, this work will be of very high interest to scientists and clinicians in the HIV cure/persistence fields.

Reviewed by eLife, Rapid Reviews Infectious Diseases

Antiretroviral therapy retention, adherence, and clinical outcomes among postpartum women with HIV in Nigeria

1. Clara M. Young
2. Charlotte A. Chang
3. Atiene S. Sagay
4. Godwin Imade
5. Olabanjo O. Ogunsola
6. Prosper Okonkwo
7. Phyllis J. Kanki

Reviewed by Rapid Reviews Infectious Diseases

Age and gender profiles of HIV infection burden and viraemia: novel metrics for HIV epidemic control in African populations with high antiretroviral therapy coverage

1. Andrea Brizzi
2. Joseph Kagaayi
3. Robert Ssekubugu
4. Lucie Abeler-Dörner
5. Alexandra Blenkinsop
6. David Bonsall
7. Larry W. Chang
8. Christophe Fraser
9. Ronald M. Galiwango
10. Godfrey Kigozi
11. Imogen Kyle
12. Mélodie Monod
13. Gertrude Nakigozi
14. Fred Nalugoda
15. Joseph G. Rosen
16. Oliver Laeyendecker
17. Thomas C. Quinn
18. M. Kate Grabowski
19. Steven J. Reynolds
20. Oliver Ratmann

Reviewed by Rapid Reviews Infectious Diseases

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV

1. Céline Fombellida-Lopez
2. Aurelija Valaitienė
3. Lee Winchester
4. Nathalie Maes
5. Patricia Dellot
6. Céline Vanwinge
7. Aurélie Ladang
8. Etienne Cavalier
9. Fabrice Susin
10. Dolores Vaira
11. Marie-Pierre Hayette
12. Catherine Reenaers
13. Michel Moutschen
14. Courtney V Fletcher
15. Alexander O Pasternak
16. Gilles Darcis

• Curated by eLife

  eLife Assessment

  This valuable clinical trial compares the impact of dolutegravir intensification on longitudinal measures of total HIV DNA and day 84 measures of intact HIV DNA. The trial was well-designed, and the paper is easy to read and provides hypothesis generation-level evidence that treatment intensification might decrease intact HIV DNA level in some people after 3 months. The findings are solid, with significant limitations being that study endpoints and hypotheses were not precisely defined prior to the trial, and that effect size is limited and inconsistent across trial participants.

Reviewed by eLife